S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma

European Journal of Cancer

Volumn 49, Issue 12, 2013, Pages 2643-2653

  Bachet, Jean Baptiste ^a,b,c,d   Maréchal, Raphael ^d   Demetter, Pieter ^d   Bonnetain, Franck ^e   Cros, Jérôme ^f   Svrcek, Magali ^a,g   Bardier Dupas, Armelle ^a,c   Hammel, Pascal ^f   Sauvanet, Alain ^f   Louvet, Christophe ^a,h   Paye, François ^a,g   Vaillant, Jean Christophe ^a,c   André, Thierry ^a,g   Closset, Jean ^d   Salmon, Isabelle ^d   Emile, Jean François ⁱ   Van Laethem, Jean Luc ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b University of Versailles Saint Quentin en Yvelines   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ERASME HOSPITAL   (Belgium)

^e Georges Francois Leclerc Cancer Center   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h INSTITUT MUTUALISTE MONTSOURIS   (France)

ⁱ HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Adjuvant therapy; Gemcitabine; Pancreatic adenocarcinoma; S100A2

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; FLUOROURACIL; GEMCITABINE; PROTEIN KINASE LKB1; S100A2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ADJUVANT THERAPY; GEMCITABINE; PANCREATIC ADENOCARCINOMA; S100A2;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMOTACTIC FACTORS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879912056     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.017     Document Type: Article

References (37)

1. M. Carpelan-Holmström, S. Nordling, and E. Pukkala Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry Gut 54 2005 385 387
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277
4. J.P. Neoptolemos, D.D. Stocken, and H. Friess A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
5. J.P. Neoptolemos, D.D. Stocken, and C. Bassi Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
6. N.B. Jamieson, C.R. Carter, C.J. McKay, and K.A. Oien Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis Clin Cancer Res 17 2011 3316 3331
7. R.A. Smith, J. Tang, C. Tudur-Smith, J.P. Neoptolemos, and P. Ghaneh Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer Br J Cancer 104 2011 1440 1451
8. I. Salama, P.S. Malone, F. Mihaimeed, and J.L. Jones A review of the S100 proteins in cancer Eur J Surg Oncol 34 2008 357 364
9. K. Ohuchida, K. Mizumoto, and N. Ishikawa The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target Clin Cancer Res 11 2005 7785 7793
10. K. Ohuchida, K. Mizumoto, and Y. Miyasaka Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis J Pathol 213 2007 275 282
11. A.V. Biankin, J.G. Kench, and E.K. Colvin Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer Gastroenterology 137 2009 558 568
12. L.M. McShane, D.G. Altman, and W. Sauerbrei Reporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 2005 387 391
13. J.B. Bachet, R. Maréchal, and P. Demetter Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma Ann Oncol 23 2012 2327 2335
14. R. Maréchal, J.B. Bachet, and J.R. Mackey Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma Gastroenterology 143 2012 664 674
15. J. Concato, P. Peduzzi, T.R. Holford, and A.R. Feinstein Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy J Clin Epidemiol 48 1995 1495 1501
16. T. Conroy, F. Desseigne, and M. Ychou FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
17. D.D. von Hoff, R.K. Ramanathan, and M.J. Borad Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol 29 2011 4548 4554
18. D.D. von Hoff, T.J. Ervin, and F.P. Arena Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) J Clin Oncol 31 2013 1234 [abstract 148]
19. R. Donato Intracellular and extracellular roles of S100 proteins Microsc Res Tech 60 2003 540 551
20. G. Feng, X. Xu, E.M. Youssef, and R. Lotan Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis Cancer Res 61 2001 7999 8004
21. E. Bulk, B. Sargin, and U. Krug S100A2 induces metastasis in non-small cell lung cancer Clin Cancer Res 15 2009 22 29
22. D. Matsubara, T. Niki, and S. Ishikawa Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes Cancer Sci 96 2005 844 857
23. R. Luthra, T.T. Wu, and M.G. Luthra Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation J Clin Oncol 24 2006 259 267
24. J.A. Gollob, and C.J. Sciambi Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells Clin Cancer Res 13 2007 5219 5225
25. S. Bruheim, Y. Xi, J. Ju, and O. Fodstad Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide Clin Cancer Res 15 2009 7161 7169
26. G. Chinnadurai, S. Vijayalingam, and S.B. Gibson BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions Oncogene 27 2009 S114 S127
27. H.M. Sowter, M. Ferguson, and C. Pym Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade J Pathol 201 2003 573 580
28. A. Giatromanolaki, M.I. Koukourakis, and H.M. Sowter BNIP3 expression is linked with hypoxiaregulated protein expression and with poor prognosis in non-small cell lung cancer Clin Cancer Res 10 2004 5566 5571
29. S. Kothari, J. Cizeau, and E. McMillan-Ward BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF Oncogene 22 2003 4734 4744
30. J. Okami, D.M. Simeone, and C.D. Logsdon Silencing of the hypoxiainducible cell death protein BNIP3 in pancreatic cancer Cancer Res 64 2004 5338 5346
31. P.C. Mahon, P. Baril, and V. Bhakta S100A4 contributes to the suppression of BINP3 expression, chemoresistance, and inhibition of apopotosis in pancreatic cancer Cancer Res 67 2007 6786 6795
32. M. Erkan, J. Kleef, and I. Esposito Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis Oncogene 24 2005 4421 4432
33. M. Akada, T. Crnogorac-Jurcevic, and S. Lattimore Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer Clin Cancer Res 11 2005 3094 3101
34. D. Manka, and D.E. Millhorn A potential molecular link between aerobic glycolysis and cancer Cell Cycle 5 2006 343 344
35. E.A. Collisson, A. Sadanandam, and P. Olson Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Nat Med 17 2011 500 503
36. S.J. Mandrekar, and D.J. Sargent Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges J Clin Oncol 27 2009 4027 4034
37. M.A. Tempero, K.A. Winter, and G.E. Kim S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): a secondary analysis of RTOG 9704 J Clin Oncol 29 2011 1234 [abstract 4118]